NASDAQ Markets
· Apr 26, 2025 4:06 AM EDT
Not market news
Innovent Biologics : China's NMPA Approves Limertinib For The First-line Treatment Of Lung Cancer
(RTTNews) - Innovent Biologics Inc. announced that China's National Medical Products Administration or NMPA has approved the New Drug Application (NDA) for limertinib as the first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NS
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
